Aileron Therapeutics Inc
NASDAQ:RNTX
Intrinsic Value
The intrinsic value of one RNTX stock under the Base Case scenario is 0.59 USD. Compared to the current market price of 1.54 USD, Aileron Therapeutics Inc is Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Aileron Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Aileron Therapeutics Inc
Balance Sheet Decomposition
Aileron Therapeutics Inc
Current Assets | 18.7m |
Cash & Short-Term Investments | 17.7m |
Other Current Assets | 1m |
Non-Current Assets | 85.5m |
PP&E | 1k |
Intangibles | 85.5m |
Other Non-Current Assets | 2k |
Free Cash Flow Analysis
Aileron Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Aileron Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-29.6m
USD
|
Operating Income
|
-29.6m
USD
|
Other Expenses
|
376k
USD
|
Net Income
|
-29.2m
USD
|
RNTX Profitability Score
Profitability Due Diligence
Aileron Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Aileron Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
RNTX Solvency Score
Solvency Due Diligence
Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNTX Price Targets Summary
Aileron Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for RNTX is 7.14 USD with a low forecast of 7.07 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for ALRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one RNTX stock under the Base Case scenario is 0.59 USD.
Compared to the current market price of 1.54 USD, Aileron Therapeutics Inc is Overvalued by 61%.